Cochran Q, Fusco A, Levis B, Weber R, Hsu R, Frost K, Millner C, Barnett S, Sherman C, Markarian C, Fusco J, Osterman M, Sarkar S, Vannappagari V, van Wyk J, Fusco G. The relationship between healthcare provider characteristics and PrEP knowledge, perceived effectiveness, and prescription practices: A CHORUS Healthcare Professional Survey. In: The Association of Nurses in AIDS Care Conference (ANAC). Philadelphia, PA; 2025.
Research Category: Oral Presentations
390 – Lenacapavir Adherence and Effectiveness Over 2 Years of Use in the OPERA Cohort
Mounzer K, Brunet L, Hsu R, Lackey PC, Sension M, Wohlfeiler MB, Dunn K, Fusco J, Fusco G. 390 – Lenacapavir Adherence and Effectiveness Over 2 Years of Use in the OPERA Cohort. IDWeek. Atlanta, GA, USA; October 19-22, 2025.
Real-world Effectiveness of CAB+RPV LA in Individuals with HIV Viremia at Therapy Initiation
Hsu RK, Sension M, Fusco JS, Brunet L, Levis B, Cochran Q, Sridhar G, Vannappagari V, Van Wyk J, Wohlfeiler M, Fusco GP. Real-world Effectiveness of CAB+RPV LA in Individuals with HIV Viremia at Therapy Initiation. 13th International AIDS Society Conference on HIV Science (IAS). Kigali, Rwanda; July 13-17, 2025
Clinical outcomes among women receiving CAB+RPV LA in the OPERA cohort: subgroup differences based on race, BMI, and age
Altamirano J, Levis B, Markarian C, Cochran Q, Sherman C, Toeque M-G, Armas L, Sridhar G, Vannappagari V, Brown K, Fusco JS. Clinical outcomes among women receiving CAB+RPV LA in the OPERA cohort: subgroup differences based on race, BMI, and age. In: 15th International Workshop on Women & HIV. Barcelona, Spain; April 4-5, 2025
O-20 HBV-HIV Co-Infection & Tenofovir Interruption in the United States: Monitoring Practices and Incidence of Hepatitis B Reactivation or Hepatitis Flare
Dieterich DT, Brunet L, Hsu RK, Pierone Jr G, Mounzer K, Weber RP, Dunbar MS, Gruber J, Yee LJ, Frenette C, Fusco GP. O-20 HBV-HIV Co-Infection & Tenofovir Interruption in the United States: Monitoring Practices and Incidence of Hepatitis B Reactivation or Hepatitis Flare. Global Hepatitis Summit. Los Angeles, CA, USA; March 18-21, 2025
Real World Data on On-Time Dosing, HIV Testing and HIV Acquisition from the OPERA Cohort
Mills A, Brunet L, Frost K, Hsu R, Pierone Jr G, Sension M, Lackey P, Mounzer K, Wohlfeiler M, Fusco J, Brown C, Vannappagari V, Aboud M, Budnik P, Fusco G. Cabotegravir Long-Acting for Pre-Exposure Prophylaxis (PrEP): Real World Data on On-Time Dosing, HIV Testing and HIV Acquisition from the OPERA Cohort. IDWeek. Los Angeles, CA, USA; October 16-19, 2024
Suppressed Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide vs. Dolutegravir/Lamivudine: Virologic Failure and Durability
Pierone G, Brunet L, Fusco J, Sension M, Dunbar M, Gruber J, Dieterich D, Fusco G. Suppressed Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide vs. Dolutegravir/Lamivudine: Virologic Failure and Durability. IDWeek. Boston, MA, USA; October 11-15, 2023
Real-World Use of Long-Acting Cabotegravir + Rilpivirine in People with HIV with Detectable Viral Loads at Initiation: Findings from the OPERA® Cohort
Hsu R, Sension M, Fusco F, Brunet L, Cochran Q, Sridhar G, Vannappagari V, van Wyk J, Wohlfeiler M, Fusco G. Real-World Use of Long-Acting Cabotegravir + Rilpivirine in People with HIV with Detectable Viral Loads at Initiation: Findings from the OPERA® Cohort. IDWeek. Boston, MA; October 11-15, 2023
Real-World Use of Long-Acting Cabotegravir + Rilpivirine in the US: Effectiveness in the First Year
Sension MG, Hsu RK, Fusco JS, et al. Real-World Use of Long-Acting Cabotegravir + Rilpivirine in the US: Effectiveness in the First Year. Presented at: IDWeek, October 19-23, 2022; Washington, DC, USA
Weight gain before and after switch from TDF to TAF
Mallon P, Brunet L, Hsu R, et al. Weight gain before and after switch from TDF to TAF [OAB0604]. Presented at: 23rd International AIDS Conference; 6-10 July 2020; Virtual Meeting